值得注意的是，今年5月10日，东阳光长江药业曾与东阳光药发布联合公告，宣布二者已于当日订立合并协议。相关条件达成后，东阳光药拟以吸收合并的方式将东阳光长江药业私有化，并根据换股比率向全体换股股东发行H股。完成换股后，东阳光长江药业H股在港交所的上市地位将被撤销，换股股东将成为东阳光药股东，并且东阳光长江药业最终将在中国注销。Dongyangguang Changjiang Pharmaceutical (01558) rose nearly 9% in the intraday period. As of press release, it was up 5.87% to HK$10.1, with a turnover of HK$0.132 billion.
The Zhitong Finance App learned that Dongyang Changjiang Pharmaceutical (01558) rose nearly 9% in the intraday period. As of press release, it had risen 5.87% to HK$10.1, with a turnover of HK$0.132 billion.
According to the news, on December 11, Dongyangyang Pharmaceutical, the controlling shareholder of Dongyangguang Changjiang Pharmaceutical, submitted a prospectus to the Hong Kong Stock Exchange to be listed in Hong Kong through an introduction. According to reports, Dongyang Pharmaceutical was founded in 2003 and is a comprehensive pharmaceutical company that focuses on innovative drugs, as well as improved new drugs, generic drugs, and biosimilar drugs, and strategically focuses on the treatment of infections, chronic diseases, and tumors.
It is worth noting that on May 10 this year, Dongyangguang Changjiang Pharmaceutical and Dongyangyang Pharmaceutical issued a joint announcement announcing that the two had signed a merger agreement on the same day. After the relevant conditions are met, Dongyang Pharmaceutical plans to privatize Dongyang Changjiang Pharmaceutical through absorption and merger, and issue H shares to all shareholders based on the share exchange ratio. After completing the share exchange, Dongyangguang Changjiang Pharmaceutical's H share listing status on the Hong Kong Stock Exchange will be withdrawn, the shareholder will become a shareholder of Dongyang Pharmaceutical, and Dongyang Changjiang Pharmaceutical will eventually be cancelled in China.
